Skip Navigation LinksIIBR > Research & Development > Patents and applications > EVOXAC - Ethical drug for Sjogren Syndrome

EVOXAC - Ethical drug for Sjogren Syndrome

IIBR's CNS Project - Small molecules development

IIBR's CNS team, developed a few chemical molecules that can be used as a basis for the development of an ethical drug aiming to treat CNS neurodegenerative diseases including Alzheimer's disease

  • First Generation of Drugs: Development of an ethical drug AF102B for the treatment of “Sjogren Syndrome", one of a few ethical drugs that were developed in Israel
  • AF102B was initially designed to treat Alzheimer disease but due to business considerations, its indication was modified to treat dry mouth and dry eyes known as “Sjogren's Syndrome".
  • In 2000, “EVOXAC" (aka: Cevimeline) was approved by the FDA and was marketed as an ethical drug in USA

  • In 2001, Japan Health Ministry approved “EVOXAC" (aka: Cevimeline) for treatment of Sjogren's Syndrome.


    “Evoxac" was disturbed under patent protection: in the USA until 7/2013 and Japan until 5/2016​